Obstructive Sleep Apnea (OSA) Drugs Research Report, Share, and Forecast to 2025

Posted by rekha on November 5th, 2019

“The Global Obstructive Sleep Apnea (OSA) Drugs Market was valued at US$ 1,132.4 Mn in 2018 and is expected to grow at a significant CAGR over six years forecast period 2019-2025 owing to rising prevalence of obstructive sleep apnea and its comorbidities”

Precision Business Insights (PBI) in its report titled “Global Obstructive Sleep Apnea (OSA) Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over six years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The global obstructive sleep apnea (OSA) drugs market was valued at US$ 1,132.4 Mn in 2018 and growing at a CAGR of 10.5% over the forecast period owing to increasing prevalence of obstructive sleep apnea coupled with rising geriatric population. For instance, currently 1.5 million in the United Kingdom are living with obstructive sleeping apnea and around 667,000 (45 percent) of the 1.5 million people estimated to be living with obstructive sleep apnea in UK have the moderate to severe forms of disorders. However, only 330,000 are receiving the treatment they need. According to the Population Reference Bureau Report, the number of Americans ages 65 and older is projected to more than double from 46 million today to over 98 million by 2060, and the 65-and-older age group’s share of the total population will rise to nearly 24 percent from 15 percent. Moreover, development and focus on approval of new drugs and market players focus on creating awareness among the OSA patients to understand the burden of the disease is expected to drive the market growth over the forecast years. However, non-availability of regular medical reimbursement policies and side effects related to the OSA drugs are anticipated to hinder the growth of the market.

Global obstructive sleep apnea (OSA) drugs market segmented on the basis of drugs, distribution channel, and region.

Request for Sample Report @ https://www.precisionbusinessinsights.com/request-sample?product_id=16861

Benzodiazepines segment accounted for higher revenue share

Based on drugs, global obstructive sleep apnea (OSA) drugs market segmented into CNS Stimulants, Benzodiazepines, and Non-Benzodiazepines. Benzodiazepines segment accounted for the largest market share in 2018 with respect to revenue owing to increasing focus on generic version of OSA products and launch of new products in the market are expected to drive the growth of the market. Availability of favorable reimbursement policies for the drugs are anticipated to boost the growth of the market.

North America holds leading position in Global Obstructive Sleep Apnea (OSA) Drugs Market

PBI’s global obstructive sleep apnea (OSA) drugs market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is expected to account for larger revenue share in 2018 and the same trend is projected to follow over 2019-2025 owing to increasing prevalence of obstructive sleep apnea in the region and growing number of geriatric population and availability of advanced healthcare infrastructure in the region and favorable insurance policies for the treatment of obstructive sleep apnea patients are expected to drive the growth of the market. According to the Population Reference Bureau Report, the number of Americans ages 65 and older is projected to more than double from 46 million today to over 98 million by 2060, and the 65-and-older age group’s share of the total population will rise to nearly 24 percent from 15 percent. Europe and Asia Pacific are expected to grow with significant growth over the future years owing to rising number of elderly population and improvement in healthcare infrastructure fuels the growth of the market over the future years.

Recent Developments in the Global Obstructive Sleep Apnea (OSA) Drugs Market

• In June 2016, In U.S Mylan launched Armodafinil Tablets of 50, 150 and 250 mg, the generic version of Cephalon’s Nuvigil.
• For instance, in June 2018, Specialty generics company Heritage Pharmaceuticals has introduced its generic Provigil (modafinil tablets), which are available in 100 mg and 200 mg dose strengths
• In June 2016, Mylan N.V has announced the final USFDA approval ANDA i.e. Armodafinil tablets 50 mg, 150 mg, and 250 mg to launch in the United States market.

Key player’s profiles in the report are Biogen, Inc (U.S)., Pfizer, Inc. (U.s), Johnson & Johnson Services, Inc. (U.S), Otsuka America Pharmaceutical, Inc. (U.S), Eli Lilly & Company (U.S),  Merck & Co., Inc. (U.S), AstraZeneca (UK), Novartis AG (Switzerland),  Teva Pharmaceutical Industries Ltd.(Israel) and Shire Plc. (Ireland).

Detailed Segmentation

By Drugs     

o   CNS Stimulants

o   Benzodiazepines

o   Non-Benzodiazepines

By Distribution Channel  

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies  

Geography

o     North America

• U.S
• Canada

o     Europe

• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

o     Asia-Pacific

• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific

o     Latin America

• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America

o     Middle East and Africa (MEA)

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/global-obstructive-sleep-apnea-drugs-market/